LIFE - aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

• aTyr Pharma produced some surprisingly strong results from recent trials of its lead drug candidate ATYR1923, and its share price has skyrocketed.
• ATYR1923 is indicated for Pulmonary Sarcoidosis - a ~200k patient population - but could address the $2-$3bn wider ILD market.
• The company's pipeline is based around founder Paul Schimmel, of the Scripps Institute, and is based around the biology of the extracellular activity of histidyl-tRNA synthetase.
• It is unique and appears to be quite promising - the company has built an intellectual property portfolio covering >300 protein compositions targeting inflammation, fibrosis and oncology.
• Analysts have set a consensus price target of ~$19 for aTyr stock, and I would concur that the company ought to be valued >$500m. I would avoid buying now at the peak of the hype cycle, but long term I see >50% upside and perhaps substantially more.

For further details see: